ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0123

The Impact of Sedentary Behavior and Physical Activity Level on Clinical Parameters and Quality of Life in Patients with Primary Antiphospholipid Syndrome (PAPS)

Carla Silva1 and Danieli Andrade2, 1University of Sao Paulo, Salvador, Bahia, Brazil, 2University of São Paulo, São Paulo, SP, Brazil

Meeting: ACR Convergence 2024

Keywords: antiphospholipid syndrome, Damage Index, health status, physical activity, SF36

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Antiphospholipid Syndrome Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: PAPS is an autoimmune disease marked by thrombosis, obstetric poor outcomes and antiphospholipid antibodies. Despite treatment, APS is associated with high morbidity and mortality, mainly from thrombotic events and cardiovascular risk factors (CVRF). This study evaluates the corelation between sedentary time, physical activity and clinical parameters in PAPS.

Methods: This cross-sectional study included 62 patients with thrombotic PAPS classified by Sydney criteria (1), without severe physical limitations. Sedentary time and physical activity were measured using activPALmicro™ accelerometers over 7 days and analyzed with ActivPAL3™ software. Variables included time spent in sedentary behavior, sitting/lying, light physical activity (LPA), and moderate to vigorous physical activity (MVPA). Thrombotic risk was evaluated using the Adjusted Global AntiPhospholipid Syndrome Score (aGAPSS), damage by the Damage Index in APS (DIAPS) and quality of life with the SF-36 questionnaire. Descriptive statistics were calculated as mean ± standard deviation and percentages. Normality was tested with the Shapiro-Wilk test. Mann-Whitney and Spearman correlation tests were used. Multiple linear regression models were proposed. Analyzes were performed with 5% significance level using Jamovi and R.

Results: Table 1 summarizes data in PAPS patients, predominantly female (89%), with age of 43.8±10.5years and BMI of 31.3±7 kg/m². CVRF included hypertension (40%) dyslipidemia (40%) and BMI over 30kg/m² (53,2%). Most patients were positive for lupus anticoagulant (92%), with 27% having triple positivity. PAPS DIAPS was 3.4±2.8  and aGAPSS was 9.6±4. Patients presented 9±2.6h of daily sedentary time, with only 12.7% meeting the recommended 150min of weekly MVPA. No significant correlations were found between sedentary time, physical activity levels and aGAPSS scores. Patients with higher thrombosis recurrence presented lower standing time (p=0.006) and a tendency towards longer sedentary time (p=0.059).

DIAPS was negatively correlated with higher MPVA (p< 0.05; rho= -0.32) and with SF-36 domains: physical (rho= -0.33), emotional (rho= -0.35), energy/vitality (rho= -0.27), physical (rho= -0.29), and mental (rho= -0.29) scores (Fig 1). Positive correlations (p< 0.05) were found between MVPA and SF-36 domains: physical aspect (rho= 0.38), functional capacity (rho=0.32), energy/vitality (rho=0.28), and physical aspect (rho=0.37) (Fig 1). In the multiple linear regression model (table 2) between independent variables and DIAPS, physical activity showed a trend towards damage reduction: LPA might affect DIAPS (β= -0.019, p=0.055) and MVPA negatively (β= -0.008, p=0.067).

Conclusion: This study suggests a correlation between physical activity and better health outcomes in PAPS. Higher levels of MVPA were inversely associated with DIAPS, and increased physical activity improved the perception of quality of life. This study suggests that PAPS should be oriented to remain active.

Supporting image 1

Legend: BMI, body mass index; WC, waist circumference; CVD, cardiovascular disease; AC, Abdominal circumference; DVT, deep vein thrombosis; PE, pulmonary embolism; aβ2GPI, anti-beta2-glycoprotein I; DIAPS, damage index in antiphospholipid syndrome; aGAPSS, adjusted global antiphospholipid syndrome score; LPA, Light Physical Activity; MVPA, moderate to vigorous physical activity, RR, reference range.

Supporting image 2

Fig 1 – Spearman Correlation: physical activity levels between DIAPS and SF_36 domains. Legend: LPA, Light Physical Activity; MVPA, moderate to vigorous physical activity, DIAPS, damage index in antiphospholipid syndrome. *Correlation is significant at the 0.05 level. **Correlation is significant at the 0.01 level.

Supporting image 3

Table 2 – Comparison of Multiple Linear Regression Models Controlled for Age, Disease Duration, Number of Total Thrombotic Events, and Physical Activity Level with DIAPS as the Dependent Variable Legend: LPA, Light Physical Activity; MVPA, moderate to vigorous physical activity. *p<0,05.


Disclosures: C. Silva: None; D. Andrade: None.

To cite this abstract in AMA style:

Silva C, Andrade D. The Impact of Sedentary Behavior and Physical Activity Level on Clinical Parameters and Quality of Life in Patients with Primary Antiphospholipid Syndrome (PAPS) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-sedentary-behavior-and-physical-activity-level-on-clinical-parameters-and-quality-of-life-in-patients-with-primary-antiphospholipid-syndrome-paps/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-sedentary-behavior-and-physical-activity-level-on-clinical-parameters-and-quality-of-life-in-patients-with-primary-antiphospholipid-syndrome-paps/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology